AI-Selected Mid-Cap Stocks Outperform Benchmark, Led by 66% Gain in Amneal Pharma

An AI-driven stock selection strategy focused on mid-cap equities has significantly outpaced its benchmark in 2026, with six of its current holdings posting gains between 13% and 66% since their inclusion. The top performer in the "Mid-Cap Movers" strategy, a model from Investing.com's ProPicks, is generic drug manufacturer Amneal Pharmaceuticals (NASDAQ:AMRX).

Strategy Outperforms by 34 Points

According to the source data, the AI-powered strategy has returned 44.85% year-to-date in 2026, generating an excess return of 34.65 percentage points over its benchmark, the S&P Midcap 400 index. Since its launch in October 2023, the strategy is reportedly up 112.05%.

The model identifies and equally weights 20 stocks each month with market capitalizations between $2 billion and $10 billion. Six current holdings have produced notable gains since being added to the portfolio:

• Amneal Pharmaceuticals (AMRX): +66.28% since June 1, 2026
• Insight Enterprises (NSIT): +48.86% since July 1, 2026
• Paycom (PAYC): +20.35% since October 1, 2026
• PVH Corp (PVH): +15.61% since October 1, 2026
• Robert Half (RHI): +14.18% since October 1, 2026
• Fortune Brands (FBIN): +13.25% since October 1, 2026

Context: Mid-Caps and Interest Rate Risk

Ad

The performance comes as investors closely watch the Federal Reserve, with a rate decision expected this Wednesday. Mid-cap companies are often considered more sensitive to interest rate policy than their large-cap counterparts due to higher leverage and greater exposure to the domestic economy.

A primer from KPMG cited in the source material suggests the Fed will likely hold rates at the upcoming meeting, but notes a potential quarter-point hike remains a possibility in December. Such a "higher-for-longer" rate environment could present headwinds for this segment of the market.

Analysis and Caveats

While the headline performance is strong, four of the six top-performing stocks—Paycom, PVH, Robert Half, and Fortune Brands—were added during the October rebalance, making their double-digit gains very recent. Past performance is not an indicator of future returns.

Furthermore, the source notes that the consensus analyst price target for Amneal Pharmaceuticals is now close to its current trading level, suggesting Wall Street may view the stock as fairly valued after its run-up. Two other companies, Paycom and Insight Enterprises, face potential event risk with third-quarter earnings reports scheduled in the coming days.